Introduction & Objective: To evaluate the efficacy and safety of mazdutide, a once-weekly GLP-1 and glucagon receptor dual agonist, in Chinese participants with overweight or obesity.

Methods: In this phase 3 randomized, double-blind, placebo-controlled trial (NCT05607680), we assigned 610 Chinese adults with a BMI of 28 kg/m2 or more, or 24 kg/m2 or more and at least one weight-related comorbidity, in a 1:1:1 ratio to receive once-weekly, subcutaneous mazdutide 4 mg, 6 mg or placebo for 48 weeks. Co-primary endpoints were the percentage change in weight from baseline and a weight reduction of 5% or more at week 32.

Results: At baseline, the mean body weight was 87.2 kg, the mean BMI was 31.1 kg/m2, and 83.1% of participants had a BMI of 28 kg/m2 or more. Mazdutide met co-primary endpoints and all key secondary endpoints, demonstrating superiority to placebo on body weight changes, weight-loss targets, and improvements on multiple cardiometabolic risk factors (Table). Mazdutide was well tolerated, with adverse events leading to treatment discontinuation reported in 1.5% of participants with mazdutide 4 mg, 0.5% with mazdutide 6 mg and 1.0% with placebo. The most frequently reported adverse events were gastrointestinal, mostly mild to moderate in severity.

Conclusion: In Chinese adults with overweight or obesity, mazdutide provides significant reductions in body weight and cardiometabolic risk factors.

Disclosure

L. Ji: None. H. Jiang: None. H. Li: None. J. Tian: None. D. Liu: None. Y. Zhao: None. J. Gu: None. Z. Liu: Employee; Innovent Biologics. H. Deng: Employee; Innovent. Y. Wang: Employee; Innoventbio. L. Li: Employee; innovent biologics. Stock/Shareholder; innovent biologics. L. Qian: Employee; Innoventbio.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.